Birch Pollen Allergy Clinical Trial
Official title:
Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure
NCT number | NCT02074930 |
Other study ID # | LPrep |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | February 17, 2014 |
Last updated | April 14, 2014 |
Start date | February 2014 |
Verified date | April 2014 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | Switzerland: Ethikkommission |
Study type | Interventional |
It is an open-label physiological investigation of the allergic skin reactivity to epicutaneous allergen exposition in 20 allergic patients in two different skin conditions. The focus of the study is on the skin preparation/condition and not on the specific allergen or allergy, but for reasons of homogeneity a single allergic disease, birch pollen allergy was chosen as the basis for the testing. In order to evaluate the effects of the two different skin preparation techniques an intraindividual comparison of the skin reactivity in terms of the immediate phase I reaction to serial dilutions of birch pollen extracts was chosen. The serial dilution approach allows a dose dependent effect evaluation and comparison of the sensitivity. The differences will be explained mainly by the two different skin preparations allowing a quantitative comparison of these techniques.
Status | Completed |
Enrollment | 20 |
Est. completion date | |
Est. primary completion date | April 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Written informed consent, - 18-65 years old (male or female), - a positive clinical history for inhalant allergy presumably due to birch pollen, - positive screening prick test (mean wheal diameter bigger or equal than 3mm) to birch pollen allergen solution, - a mean wheal size of bigger or equal than 7mm2 obtained in the screening prick test with histamine dihydrochloride (10mg/ml) Exclusion Criteria: - Impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent, - enrolment into a clinical trial within last 4 weeks, - pregnancy or nursing, - positive skin reaction in the screening prick test to NaCl, - currently suffering from allergy symptoms, - history of systemic reactions to allergens, - severe diseases influencing the results of the present study by discretion of the investigator, - immunotherapy with the allergen preparation during the past two years, - skin lesions and excessive hair-growth in the skin test areas, - treatment with prohibited concomitant medications with the exception of medications with local effects which will not influence the results of the skin prick tests, - known or suspected non-compliance, drug or alcohol abuse |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Zurich, Division of Dermatology | Zurich | ZH |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Wheal Size (mm^2) | The minimal protein concentration eliciting a wheal size of >0mm^2 will be compared between the two different skin preparation techniques with a Wilcoxon signed ranks test. | The primary outcome will be assesed after 15min after allergen exposure | No |
Secondary | Wheal Size | The wheal sizes at 10 HEP, 1 HEP, 0.1 HEP and 0.01 HEP/ml will be compared between the two skin preparation techniques (either with a paired-samples t-test if normally distributed or with a Wilcoxon signed ranks test). | Wheal size will be assessed after 15 Minutes | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06037148 -
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
|
Phase 1 | |
Completed |
NCT04912076 -
S.C. Immunotherapy With BM41 in Patients With Allergic Rhino-conjunctivitis Caused by Birch Pollen
|
Phase 1 | |
Recruiting |
NCT05346718 -
Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis
|
N/A | |
Completed |
NCT01137357 -
Probiotics for Reduction Of Markers In Subjects With Allergy
|
N/A | |
Active, not recruiting |
NCT05668390 -
Safety and Efficacy of STALORAL® Birch 300 IR in a Paediatric Population With Birch Pollen-induced ARC w/o Asthma
|
Phase 3 | |
Not yet recruiting |
NCT02146300 -
Effect of the Nasal Provocation on the Breathing Style
|
N/A | |
Completed |
NCT01449786 -
Sublingual Immunotherapy of Birch Pollen Associated Apple Allergy
|
Phase 2 | |
Completed |
NCT03969849 -
Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants
|
Phase 1 | |
Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
Completed |
NCT01628484 -
Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation
|
Phase 1 | |
Completed |
NCT00932607 -
SUBLIVAC® Birch PROBE Study
|
Phase 2 | |
Completed |
NCT00266526 -
Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV
|
Phase 2 | |
Completed |
NCT02143583 -
Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment
|
Phase 2 | |
Completed |
NCT04266028 -
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
|
Phase 1 | |
Completed |
NCT00309062 -
Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis
|
Phase 3 | |
Completed |
NCT01675791 -
A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet
|
Phase 2 |